Yonghe Sunshine

Hunan Yonghe Sunshine Biotechnology Co., Ltd. (hereinafter referred to as "Yonghe Sunshine") was founded in March 2006. It is a high-tech enterprise engaged in the research and development, production, sales, and service of in vitro diagnostic reagents and medical laboratory instruments. After more than ten years of development, Yonghe Sunshine has grown from a single biochemical reagent manufacturer into a company with significant market influence covering multiple fields including biochemical reagents, fully automated biochemical analyzers, calibrators and quality controls, fully automated glycated hemoglobin analyzers, and POCT testing systems. The company is located at *No. 101 Kangtian Road, Liuyang Economic and Technological Development Zone, and possesses a 4,000 m² garden-style factory building, a Class 100,000 cleanroom, brand-new quality inspection equipment, and a reference laboratory compliant with ISO 17025 CNAS accreditation standards. In terms of quality control, the company has consistently followed Good Manufacturing Practice (GMP) standards and has successively passed ISO 13485 medical device quality management system certification and the External Quality Assessment (EQA) program of the clinical laboratory center. For many years, the company has been dedicated to technological innovation, with a first-class R&D team and a full industry chain integrating industry, academia, and research. To further integrate premium resources and expand overall scale, Yonghe Sunshine successfully introduced Xilong Scientific (stock code: 002584) in September 2014 for capital increase and share expansion, with the company's net assets exceeding 120 million yuan. Leveraging Xilong Scientific's R&D management advantages and strong capital support, the company now has a brand-new business development platform and has begun to achieve economies of scale. Yonghe Sunshine has always taken "providing precise medical services for human health" as its mission, continuously pursuing innovation and carefully building the "Yonghe Sunshine" brand. We will always adhere to the purpose of "Innovative Technology, Leading Health" and the core values of "Innovation, Rigor, Excellence, Dedication," laying out across the entire in vitro diagnostic product industry and striving tirelessly toward the beautiful vision of "becoming a domestic IVD* system service provider." On March 9, 2017, the company was officially approved for listing on the National Equities Exchange and Quotations ("New Third Board"). Stock abbreviation: Yonghe Sunshine; Stock code: 870853.